Decreased Nucleotide Excision Repair Activity and Alterations of Topoisomerase IIα Are Associated with the in Vivo Resistance of a P388 Leukemia Subline to F11782, a Novel Catalytic Inhibitor of Topoisomerases I and II

Clinical Cancer Research

Volumn 10, Issue 9, 2004, Pages 3156-3168

  Kruczynski, Anna ^a   Barret, Jean Marc ^a   Van Hille, Benoît ^a   Chansard, Nathalie ^a   Astruc, Jackie ^a   Menon, Yoann ^a   Duchier, Carole ^a   Créancier, Laurent ^a   Hill, Bridget T ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; 6 [2 (DIMETHYLAMINO)ETHYLAMINO] 3 HYDROXY 7H INDENO[2,1 C]QUINOLIN 7 ONE; CAMPTOTHECIN; CARMUSTINE; CISPLATIN; COLCHICINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ENDONUCLEASE; ETOPOFOS; F 11782; FLUOROURACIL; GLUTATHIONE; GYRASE INHIBITOR; IRINOTECAN; MERBARONE; MESSENGER RNA; METHOTREXATE; MITOXANTRONE; NAVELBINE; PROTEIN XPG; TAFLUPOSIDE; TENIPOSIDE; TOPOTECAN; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINFLUNINE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DNA SYNTHESIS; DRUG MECHANISM; DRUG UPTAKE; ENZYME ACTIVITY; EXCISION REPAIR; FEMALE; IN VIVO STUDY; LEUKEMIA P 388; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; XERODERMA PIGMENTOSUM;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BLOTTING, NORTHERN; CATALYSIS; CELL LINE, TUMOR; CISPLATIN; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; LEUKEMIA; MICE; MICE, INBRED DBA; MUTATION, MISSENSE; NAPHTHALENES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ORGANOPHOSPHORUS COMPOUNDS; PYRANS; RNA, MESSENGER;

EID: 2442585381     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1305-2     Document Type: Article

References (41)

1. Pommier Y. DNA topoisomerase II inhibitors. In: Teicher BA, editor. Cancer therapeutics: experimental and clinical agents. Totowa, NJ: Humana Press Inc.; 1997. p. 153-74.
2. Beck WT, Morgan SE, Mo YY, Bhat UG. Tumor cell resistance to DNA topoisomerase II inhibitors: new developments. Drug Resist Updat 1999;2:382-9.
3. El-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 2002;9:79-87.
4. Larsen A, Skladanowski A. Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim Biophys Acta 1998;1400:257-74.
5. Pommier Y, Pourquier P, Urasaki Y, Wu J, Laco GS. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 1999;2:307-18.
6. Perrin D, van Hille B, Barret JM, et al. F11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action. Biochem Pharmacol 2000;59:807-19.
7. Jensen LH, Renodon-Cornière A, Nitiss KC, et al. A dual mechanism of action of the anticancer agent F11782 on human topoisomerase Ha. Biochem Pharmacol 2003;66:623-31.
8. Barret JM, Hill BT, Olive PL. Characterization of DNA-strand breakage induced in V79 cells by F11782, a catalytic inhibitor of topoisomerases. Br J Cancer 2000;83:1740-6.
9. Barret JM, Etiévant C, Baudouin C, et al. F11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-K1 cells. Anticancer Res 2002;22:187-92.
10. Barret JM, Cadou M, Hill BT. Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F11782, a novel fluorinated epipodophylloid. Biochem Pharmacol 2002;63:251-8.
11. Kruczynski A, Etiévant C, Perrin D, et al. Preclinical antitumour activity of F11782, a novel dual catalytic inhibitor of topoisomerases. Br J Cancer 2000;83:1516-24.
12. Kruczynski A, Ricome C, Waud W, Hill BT. In vivo antitumor activity of F11782, a non-intercalating dual catalytic inhibitor of topoisomerases I and II, against a panel of human tumor xenografts. J Exp Ther Oncol 2002;2:219-27.
13. Kruczynski A, Colpaert F, Tarayre JP, et al. Preclinical in vivo antitumour activity of vinflunine, a novel fluorinated Vinca alkaloid. Cancer Chemother Pharmacol 1998;41:437-47.
14. Venditti J. Preclinical drug development: rationale and methods. Semin Oncol 1981;8:349-61.
15. Bradford M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
16. Bootsma D, Mudler MP, Cohen JA, Pot F. Different inherited levels of DNA repair replication in xeroderma pigmentosum cell strains after exposure to ultraviolets irradiation. Mutat Res 1970;9:507-16.
17. Broxterman H, Kankelma J, Pinedo H. How to probe clinical tumor samples for P-glycoprotein and multidrug resistance-associated protein. Eur J Cancer 1996;32A:1024-33.
18. Fujii H, Tanigawa N, Muraoka R, Shimomatsuya T, Tanaka T. Detection of P-glycoprotein in solid tumors by flow cytometry. Anticancer Res 1993;13:2171-6.
19. Etiévant C, Barret JM, Kruczynski A, Perrin D, Hill BT. Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Investig New Drugs 1998;16:3-17.
20. Akiyama S, Chen ZS, Sumizawa T, Furukawa T. Resistance to cisplatin. Anti-Cancer Drug Des 1999;14:143-51.
21. Kusumoto H, Rodgers QE, Boege F, Raimondi SC, Beck WT. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Cancer Res 1996;56:2573-83.
22. 2/M checkpoint and apoptotic response. Mol Pharmacol 2000;57:296-307.
23. Dereuddre S, Delaporte C, Jacquemin-Sablon A. Role of topoisomerase IIβ in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Res 1997;57:4301-8.
24. Errington F, Willmore E, Tilby MJ, et al. Murine transgenic cells lacking DNA topoisomerase IIβ are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation. Mol Pharmacol 1999;56:1309-16.
25. Nitiss JL. Mutational analysis of topoisomerase II drug action: the yeast test tube. Anticancer Drugs 1996;7:27-34.
26. Vassetzky YS, Alghisi GC, Gasser SM. DNA topoisomerase II mutations and resistance to anti-tumor drugs. BioEssays 1995;17:767-74.
27. van Hille B, Etiévant C, Barret JM, Kruczynski A, Hill BT. Characterization of the biological and biochemical activities of F11782 and bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action. Anticancer Drugs 2000;11:829-41.
28. Hotobagyi GN. Anthracyclines in the treatment of cancer: an overview. Drugs 1997;54:1-7.
29. Fujimori A, Gupta M, Hoki Y, Pommier Y. Acquired resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair. Mol Pharmacol 1996;50:1472-8.
30. Barret JM, Kruczynski A, Etiévant C, Hill BT. Synergistic effects of F11782, a novel dual catalytic inhibitor of topoisomerases I and II, in combination with other anticancer agents. Cancer Chemother Pharmacol 2002;49:479-86.
31. Dabholkar M, Vionnet J, Bostickbruton F, Yu J, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Investig 1994;94:703-8.
32. Anderson B, Sadeghi T, Siciliano M, Legerski R, Murray D. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother Pharmacol 1996;38:406-16.
33. Damia G, Imperatori L, Stefanini M, D'Incalci M. Sensitivity of CHO mutant cell lines with specific defects in nucleotides excision repair to different anti-cancer agents. Int J Cancer 1996;66:779-83.
34. Lee K, Parker R, Bohr V, Cornelison T, Reed E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis (Lond) 1993;14:2177-80.
35. Takebayashi Y, Pourquier P, Zimonjic D, et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-6.
36. Aune G, Furuta T, Pommier Y. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action. Anti-Cancer Drugs 2002;13:545-55.
37. Cooper P. Unexpected complexities of pathway interactions in repair of oxidative damage. Proc Am Assoc Cancer Res 2002;43:1180.
38. Cooper P, Nouspikel T, Clarkson S, Li G, Leadon S. Defective transcription-coupled repair of oxidative base damage in Cockayne syndrome patients from XP group G. Science (Wash DC) 1997;275:990-3.
39. Bouayadi K, Calson P, Pedrini AM, Salles B. In vitro evolution of cisplatin/DNA monoadducts into diadducts is dependent upon super-helical density. Biochem Biophys Res Commun 1992;189:111-8.
40. Huai Q, Colandene JD, Chen Y, et al. Crystal structure of NaeI: an evolutionary bridge between DNA endonuclease and topoisomerase. EMBO J 2000;19:3110-8.
41. Constantinou A, Gunz D, Evans E, et al. Conserved residues of human XPG protein important for nuclease activity and function in nucleotide excision repair. J Biol Chem 1999;274:5637-48.